In fact, immunohistochemistry analysis of Bmal1 in tumor tissues from 87 patients with pancreatic ductal adenocarcinoma showed lower levels of this protein compared with adjacent non-tumor tissues and low Bmal1 expression was associated with tumor progression and poor prognosis (143). Here, BMAL1 is linked to pancreatic ductal adenocarcinoma.